SHANGHAI and NEW YORK, April 3, 2019 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received the 2019 CMO Leadership Awards in all six core categories including Quality, Reliability, Service, Expertise, Capabilities and Compatibility across the group of Big Pharma, representing a significant leap from 2018 with one category in Reliability. These awards recognize the unwavering commitment to quality, dedication to customer service, strong operational execution, and increasing global influence achieved by WuXi Biologics in 2018.
For the 2019 CMO Leadership Awards, Life Science Leader Magazine teamed up with Industry Standard Research (ISR) to determine the award recipients. More than 120 contract manufacturers were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey, covering all sizes of companies from both Pharma industry and Biopharma industry in the U.S. and Europe.
“Over the past eight years, WuXi Biologics has gained huge support and genuine trust from our large global client base while endeavoring to maintain high levels of quality and operational excellence,” said Dr. Chris Chen, CEO of WuXi Biologics. “We are honored to receive all these six awards and will continue to enable our global clients and partners to accelerate and transform biologics discovery, development and manufacturing to benefit patients worldwide.”
Since operating its biologics manufacturing facilities in Wuxi city in 2012, which are the first in China meeting cGMP standards of the U.S., the EU as well as China, WuXi Biologics has made huge progress and became a global leader in biologics process development, continuous processing and manufacturing with disposable technologies. After approval by the U.S. FDA for the production of Trogarzo™ in 2018, WuXi Biologics has also received certificates from European Medicines Agency (EMA) for the cGMP Drug Substance (DS) and Drug Product (DP) manufacturing facilities, making it to be the first biologics company in China approved by both the U.S. FDA and EMA.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of December 31, 2018, there were a total of 205 integrated projects, including 97 projects in pre-clinical development stage, 94 projects in early-phase (phase I and II) clinical development, 13 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.